Halo Pharma Simplifies Topical Drug Product Development and Manufacturing
Global Pharmaceutical Companies Outsource Topical Products to Halo Pharma
Whippany, N.J., April 12, 2018 – Halo Pharma, a rapidly growing contract development and manufacturing organization (CDMO), offers more than 30 years’ direct experience in the production of topical drug products – from prescription dermatological drugs to over-the-counter (OTC) and high-value health and beauty products. Halo Pharma will be discussing its capabilities in topical drug products at CPhI NA, Booth 1549, at the Pennsylvania Convention Center, April 24-26.
Topical drug products, which Research and Markets predicts will reach global sales of $194.2 billion by 2024, target localized skin sites or offer systemic penetration by formulations that are easily applied and conveniently packaged. They are complex to formulate as they typically mix oil and water phases in various ratios with an active pharmaceutical ingredient and other ingredients to create a semi-solid or liquid formulation that is safe, efficacious, and patient friendly.
With topical centers of excellence in its Whippany, N.J. and Mirabel, Quebec, Canada facilities, Halo Pharma provides a one-stop-shop for global pharmaceutical companies looking to develop and manufacture compliant, high-quality gels, creams, lotions, and sterile and non-sterile ointments for a range of indications. Because Halo Pharma can formulate, develop, scale up, manufacture, and package topical drug products in contiguous, end-to-end production areas, it eliminates unnecessary changes in process and equipment, as well as knowledge gaps, that can occur when topical products are transferred.
“Halo covers the full breadth of equipment, technologies, skills, and expertise when it comes to taking a topical drug product from formulation to market,” says Lee Karras, CEO of Halo Pharma. “Our manufacturing and packaging facilities are co-located for seamless transition to commercial supply; we handle the bioequivalence (IVRT), chemistry, and microbiology testing that are essential for today’s dermatological markets. Further, we have the supply chain expertise to source the best and lowest cost materials; our equipment and processes are state-of-the-art; and we offer a packaging range that includes tubes, jars, and bottles in various sizes, including trial or sample sizes that many customers desire.”
For a detailed analysis of Halo’s topical development and manufacturing expertise, download a complimentary white paper, Aim for Quality, Simplicity, and Cost Efficiency in the Development, Scale-up, and Manufacturing of Semi-Solid Dosage Forms. The paper covers formulation selection, five key physical characteristics of product formulation, in vitro release testing (IVRT) and bioequivalence, bioburden and microbial testing, and technology and site transfer considerations.
A case study, Technology and Site Transfer of a Semi-Solid Product for Commercial Launch, is also available to learn how Halo Pharma was recently able to successfully transfer and scale up a topical ointment. Using a variety of analytical methods including IVRT, Halo was able to demonstrate bioequivalency with a reference drug without reliance on additional clinical studies. Halo manufactures the finished drug product in 900kg quantities that are packaged in 45g tubes and 2g sample packets.
Halo Pharma is prepared to formulate, develop, manufacture, and package clients’ topical prescription, OTC, and high-value health and beauty products for global distribution. To learn more about Halo Pharma’s unique capabilities in topical drug products, visit halopharma.com/topicals or see them at CPhI NA in Booth 1549.
About Halo Pharma
Halo Pharma is a rapidly growing contract development and manufacturing organization (CDMO) that provides scientific and development expertise as well as a wide spectrum of manufacturing services from its locations in Whippany, New Jersey, USA and Montreal, Quebec, Canada to its international client base. Halo offers fully integrated capabilities in a variety of dosage forms including tablets, capsules, powders, liquids, creams, sterile and non-sterile ointments and suppositories. The company is registered to work with any of these dosages in the CI-CV DEA designations. Halo Pharma’s capabilities in the areas of tech transfer, process and product development, production, scale-up/validation and analytical method development allow us to partner with clients from development through commercialization or at any point along the way. For more information please contact firstname.lastname@example.org.